Patients with a history of stroke or intracranial hemorrhage within 6 months prior to registration are not eligibleXx_NEWLINE_xXHistory of stroke within 6 months.Xx_NEWLINE_xXStroke.Xx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXKnown history of stroke or cerebrovascular accident within 6 months before enrollment.Xx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXAny history of hemorrhagic strokeXx_NEWLINE_xXHistory of stroke/intracranial hemorrhage =< 6 months prior to registrationXx_NEWLINE_xXHistory of intracranial abscess within 6 months prior to randomization.Xx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to randomizationXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months of first doseXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of ischemic stroke within 6 months prior to enrollment.Xx_NEWLINE_xXAny history of symptomatic intracranial hemorrhage.Xx_NEWLINE_xXPatients should not have a stroke or intracranial hemorrhage within last 6 monthsXx_NEWLINE_xXPatients will not be eligible if they have a history of intracranial hemorrhage in past 6 monthsXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of ischemic stroke or intracranial hemorrhage =< 180 days prior to pre-registrationXx_NEWLINE_xXHistory of stroke/intracranial hemorrhage =< 6 months prior to registrationXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXPrevious stroke < 12 monthsXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months of the first dose of study drugXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months before the first dose of study drugXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke within the last 5-yearsXx_NEWLINE_xXHistory of stroke or cerebral hemorrhage within 2 monthsXx_NEWLINE_xXEvidence of acute intracranial / intra-tumoral hemorrhage, except for participants with stable grade 1 hemorrhage.Xx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to randomizationXx_NEWLINE_xXIntracranial hemorrhage except for tumor associated micro hemorrhage.Xx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to study entryXx_NEWLINE_xXHistory of stroke or cerebral hemorrhage within 6 monthsXx_NEWLINE_xXHistory of intracranial hemorrhage (either by clinical history or neuroimaging)Xx_NEWLINE_xXHistory of stroke or cerebral hemorrhage within 2 monthXx_NEWLINE_xXPatient with stroke in the last 3 monthsXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months of screeningXx_NEWLINE_xXNo history of intracranial hemorrhageXx_NEWLINE_xXHistory of stroke within 6 monthsXx_NEWLINE_xXRelapsed/refractory MCL: History of stroke or intracranial hemorrhage within 6 months prior to signing the consentXx_NEWLINE_xXNewly diagnosed MCL: History of stroke or intracranial hemorrhage within 6 months prior to signing the consentXx_NEWLINE_xXHistory of stroke within 6 monthsXx_NEWLINE_xXHistory (within the last 3 months) or presence of stroke/cerebrovascular accidentXx_NEWLINE_xXEvidence of recent (less than 2 weeks) intracranial hemorrhage.Xx_NEWLINE_xXHave evidence of significant (ie, symptomatic) intracranial hemorrhage.Xx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXKnown history of cerebrovascular accident, myocardial infarction, or intracranial hemorrhage within 2 months of enrollment.Xx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrolmentXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 3 months prior to enrollmentXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to signing the consent.Xx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke within six monthsXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months before randomization.Xx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months before randomization.Xx_NEWLINE_xXhistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of intracranial abscess within 6 months prior to study enrolment.Xx_NEWLINE_xXHistory of stroke or clinically significant intracranial hemorrhage within 6 months before first dose of study drug.Xx_NEWLINE_xXHistory of cerebral vascular accident or stroke within the previous 2 yearsXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXKnown history of stroke or cerebrovascular accident within 6 months prior to enrollmentXx_NEWLINE_xXNo stroke or intracranial hemorrhage within the last 6 monthsXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollment.Xx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke or cerebral hemorrhage within 6 monthsXx_NEWLINE_xXKnown history of stroke or cerebrovascular accident within 6 months prior to enrollmentXx_NEWLINE_xXPatient has history of stroke or intracranial hemorrhage =< 6 months from starting study drugsXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to the first dose of study drugXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to study entryXx_NEWLINE_xXKnown history of stroke or cerebrovascular accident within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke or cerebral hemorrhage within 2 monthsXx_NEWLINE_xXActive intracranial hemorrhageXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to the first dose of ibrutinibXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollment.Xx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 12 months prior to enrollment.Xx_NEWLINE_xXSubjects with a history of stroke or intracranial hemorrhage within 6 months prior to enrollment are not eligibleXx_NEWLINE_xXKnown history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drugXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to randomizationXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to random assignmentXx_NEWLINE_xXHistory of Grade 2 (CTCAE v4) or greater acute intracranial hemorrhage.Xx_NEWLINE_xXActive gastrointestinal (GI) or intracranial hemorrhageXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to randomization; or clinically significant cardiovascular diseaseXx_NEWLINE_xXHistory of stroke within 6 months prior to study registrationXx_NEWLINE_xXHistory of stroke within 6 months of registrationXx_NEWLINE_xXHistory of stroke within 6 months prior to day 1Xx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of strokeXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months of screening would be exclusion for ibrutinib therapy but idelalisib would be an optionXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to registrationXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXKnown history of stroke or cerebrovascular accident within 6 months prior to the first dose of protocol therapy.Xx_NEWLINE_xXPatients with a history of known stroke or intracranial hemorrhage within 6 months prior to study treatment are excludedXx_NEWLINE_xXKnown history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug.Xx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollment.Xx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xX5. Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug.Xx_NEWLINE_xXKnown history of stroke or cerebrovascular accident within 6 months.Xx_NEWLINE_xXHistory of stroke within 6 monthsXx_NEWLINE_xXSubjects with severe hemorrhage, or history of severe hemorrhageXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke within 6 months prior to study enrollment.Xx_NEWLINE_xXAny known history of cerebrovascular disease including TIA, stroke or subarachnoid hemorrhageXx_NEWLINE_xXPatients with a history of intracranial hemorrhage are not eligible.Xx_NEWLINE_xXHistory of stroke within six monthsXx_NEWLINE_xXHistory (within the last 6 months) or presence of stroke/cerebrovascular accidentXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage =< 6 months prior to registrationXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to treatmentXx_NEWLINE_xXHistory of stroke or cerebral hemorrhage within 2 monthsXx_NEWLINE_xXEvidence of significant intracranial hemorrhageXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months of enrollmentXx_NEWLINE_xXStroke within the past 2 yearsXx_NEWLINE_xXHistory of strokeXx_NEWLINE_xXNo history of hemorrhagic strokeXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXDiagnosis of intracranial hemorrhage within the past 3 months, including intratumoral hemorrhage into brain metastases from a systemic cancerXx_NEWLINE_xXstroke (within the last 6 month)Xx_NEWLINE_xXAny history of significant hemorrhage (requiring hospitalization or transfusion) within the last 6 months (excluding hemorrhage during operative procedure)Xx_NEWLINE_xXEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): History of stroke or intracranial hemorrhage within 6 months prior to screeningXx_NEWLINE_xXStroke in the last six monthsXx_NEWLINE_xXPatients must not have evidence of significant intracranial hemorrhageXx_NEWLINE_xXHistory of severe brain-injury or stroke.Xx_NEWLINE_xXHistory of cerebrovascular accident (stroke)Xx_NEWLINE_xXStroke or TIA within 12 last monthsXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months prior to enrollmentXx_NEWLINE_xXHistory of stroke with the past yearXx_NEWLINE_xXHistory of stroke or intracranial hemorrhage within 6 months of first doseXx_NEWLINE_xX